The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention
Open accessAbstract
Peripheral neuropathies induced by chemotherapy (CIPN) are an increasingly frequent problem. Contrary to hematologic adverse effects, which can be treated with hematopoetic growth factors, neither prophylaxis nor specific treatment is available, and only symptomatic treatment can be offered. Neurotoxic drugs are becoming a major dose-limiting factor. The epidemiology is still unclear. Several drug-dependent pathogenetic mechanisms exist. CIPN are predominately sensory, length-dependent neuropathies that develop after a typical cumulative dose. Usually, the appearance of CIPN is dose dependent, although in at least 2 drugs (oxaliplatin and taxanes), immediate toxic effects occur. The most frequent substances causing CIPN are platin compounds, vinka alkaloids, taxanes, and bortezomib and thalidomide. The role of synergistic neurotoxicity caused by previously given chemo-therapies and concomitant chemotherapies and the role pre-existent neuropathy on the development of a CIPN is not clear. As the number of long-term cancer survivors increases and a new focus on long-term effects of chemotherapy-induced neuropathies emerge, concepts of rehabilitation need to be implemented to improve the patients' functions and quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability
Guralnik, J. M., Ferrucci, L., Simonsick, E. M., Salive, M. E., & Wallace, R. B. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320902 · Cited by 4,083
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Zarow, C., Lyness, S. A., Mortimer, J. A., & Chui, H. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.337 · Cited by 1,002
Lauria, G., Hsieh, S. T., Johansson, O., Kennedy, W. R., Leger, J. M., Mellgren, S. I., Nolano, M., Merkies, I. S. J., Polydefkis, M., Smith, A. G., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03023.x · Cited by 864
Chemotherapy‐induced neuropathy
Windebank, A. J., & Grisold, W. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00156.x · Cited by 613
Self-citationPeripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472
Total neuropathy score: Validation and reliability study
Cornblath, D. R., Chaudhry, V., Carter, K., Lee, D., Seysedadr, M., Miernicki, M., & Joh, T. (1999) · Neurology · doi:10.1212/wnl.53.8.1660 · Cited by 449
Peripheral sensory neuropathy and cisplatin chemotherapy
Roelofs, R. I., Hrushesky, W., Rogin, J., & Rosenberg, L. (1984) · Neurology · doi:10.1212/wnl.34.7.934 · Cited by 370
Gregg, R. W., Molepo, J. M., Monpetit, V. J., Mikael, N. Z., Redmond, D., Gadia, M., & Stewart, D. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.795 · Cited by 358
Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M. A., Bladé, J., Mateos, M. V., Rosiñol, L., Boccadoro, M., Cavo, M., Lokhorst, H., et al. (2011) · Blood · doi:10.1182/blood-2011-06-358812 · Cited by 352
Chemotherapy-induced peripheral neurotoxicity
Cavaletti, G., & Marmiroli, P. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.160 · Cited by 351
Self-citationSemiglazov, V. F., Semiglazov, V. V., Dashyan, G. A., Ziltsova, E. K., Ivanov, V. G., Bozhok, A. A., Melnikova, O. A., Paltuev, R. M., Kletzel, A., & Berstein, L. M. (2007) · Cancer · doi:10.1002/cncr.22789 · Cited by 333
A review on oxaliplatin-induced peripheral nerve damage
Argyriou, A. A., Polychronopoulos, P., Iconomou, G., Chroni, E., & Kalofonos, H. P. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.003 · Cited by 330
Ta, L. E., Espeset, L., Podratz, J., & Windebank, A. J. (2006) · NeuroToxicology · doi:10.1016/j.neuro.2006.04.010 · Cited by 325
Self-citationThe Challenges of Colorectal Cancer Survivorship
Denlinger, C. S., & Barsevick, A. M. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0058 · Cited by 324
Richardson, P. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07573.x · Cited by 305
Vincristine‐induced neuropathy: A clinical study of fifty leukemic patients
Sandier, S. G., Tobin, W., & Henderson, E. S. (1969) · Neurology · doi:10.1212/wnl.19.4.367 · Cited by 300
Interventions for preventing neuropathy caused by cisplatin and related compounds
Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005228.pub4 · Cited by 298
Self-citationTesticular Cancer Survivorship: Research Strategies and Recommendations
Travis, L. B., Beard, C., Allan, J. M., Dahl, A. A., Feldman, D. R., Oldenburg, J., Daugaard, G., Kelly, J. L., Dolan, M. E., Hannigan, R., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq216 · Cited by 294
Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Frigeni, B., Alberti, P., Bruna, J., Velasco, R., Argyriou, A. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds329 · Cited by 293
Self-citationGill, J. S., & Windebank, A. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1130 · Cited by 278
Self-citationKoss, M. N., Hochholzer, L., & O’Leary, T. J. (1991) · Cancer · doi:10.1002/1097-0142(19910501)67:9<2241::aid-cncr2820670905>3.0.co;2-a · Cited by 272
Postma, T. J., Vermorken, J. B., Liefting, A. J. M., Pinedo, H. M., & Heimans, J. J. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059220 · Cited by 271
Chronic Pain in the Cancer Survivor: A New Frontier
Burton, A. W., Fanciullo, G. J., Beasley, R. D., & Fisch, M. J. (2007) · Pain Medicine · doi:10.1111/j.1526-4637.2006.00220.x · Cited by 240
Chemotherapy-induced peripheral neurotoxicity
Cavaletti, G., & Marmiroli, P. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000234 · Cited by 239
Self-citationStrumberg, D., Brügge, S., Korn, M. W., Koeppen, S., Ranft, J., Scheiber, G., Reiners, C., Möckel, C., Seeber, S., & Scheulen, M. E. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf058 · Cited by 232
Oxaliplatin‐induced neurotoxicity and the development of neuropathy
Krishnan, A. V., Goldstein, D., Friedlander, M., & Kiernan, M. C. (2005) · Muscle & Nerve · doi:10.1002/mus.20340 · Cited by 216
Lobert, S., Vulevic, B., & Correia, J. J. (1996) · Biochemistry · doi:10.1021/bi953037i · Cited by 212
Attal, N., Bouhassira, D., Gautron, M., Vaillant, J. N., Mitry, E., Lepère, C., Rougier, P., & Guirimand, F. (2009) · Pain · doi:10.1016/j.pain.2009.03.024 · Cited by 195
Egbelakin, A., Ferguson, M. J., MacGill, E. A., Lehmann, A. S., Topletz, A. R., Quinney, S. K., Li, L., McCammack, K. C., Hall, S. D., & Renbarger, J. L. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22845 · Cited by 192
Peters, C. M., Jimenez-Andrade, J. M., Kuskowski, M. A., Ghilardi, J. R., & Mantyh, P. W. (2007) · Brain Research · doi:10.1016/j.brainres.2007.06.066 · Cited by 175
Relationship Between Cisplatin Administration and the Development of Ototoxicity
Rademaker-Lakhai, J. M., Crul, M., Zuur, L., Baas, P., Beijnen, J. H., Simis, Y. J. W., van Zandwijk, N., & Schellens, J. H. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.077 · Cited by 174
Toxic neuropathy in patients with pre-existing neuropathy
Chaudhry, V., Chaudhry, M., Crawford, T. O., Simmons-O’Brien, E., & Griffin, J. W. (2003) · Neurology · doi:10.1212/01.wnl.0000043691.53710.53 · Cited by 173
Characteristics of bortezomib‐ and thalidomide‐induced peripheral neuropathy
Chaudhry, V., Cornblath, D. R., Polydefkis, M., Ferguson, A., & Borrello, I. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00193.x · Cited by 172
Bernhardson, B.-M., Tishelman, C., & Rutqvist, L. E. (2007) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.12.010 · Cited by 169
Mohty, B., El-Cheikh, J., Yakoub-Agha, I., Moreau, P., Harousseau, J.-L., & Mohty, M. (2010) · Haematologica · doi:10.3324/haematol.2009.012674 · Cited by 167
Cavaletti, G., Tredici, G., Marmiroli, P., Petruccioli, M. G., Barajon, I., & Fabbrica, D. (1992) · Acta Neuropathologica · doi:10.1007/bf00227662 · Cited by 164
Self-citationBrydoy, M., Oldenburg, J., Klepp, O., Bremnes, R. M., Wist, E. A., Wentzel-Larsen, T., Hauge, E. R., Dahl, O., & Fossa, S. D. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp413 · Cited by 162
Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon Cancer
Kahn, K. L. (2010) · JAMA · doi:10.1001/jama.2010.272 · Cited by 161
Glendenning, J., Barbáchano, Y., Norman, A. R., Dearnaley, D. P., Horwich, A., & Huddart, R. A. (2010) · Cancer · doi:10.1002/cncr.24981 · Cited by 153
Cancer Survivors in the United States: A Review of the Literature and a Call to Action
Valdivieso, M., Kujawa, A. M., Jones, T. T., & Baker, L. H. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.3827 · Cited by 149
Motor neuropathy due to docetaxel and paclitaxel
Freilich, R. J., Balmaceda, C. M., Seidman, A. D., Rubin, M., & DeAngelis, L. M. (1996) · Neurology · doi:10.1212/wnl.47.1.115 · Cited by 144
Thalidomide sensory neurotoxicity
Cavaletti, G., Beronio, A., Reni, L., Ghiglione, E., Schenone, A. E., Briani, C., Zara, G., Cocito, D., Isoardo, G., Ciaramitaro, P., et al. (2004) · Neurology · doi:10.1212/wnl.62.12.2291 · Cited by 135
Self-citationMcDonald, E. S., & Windebank, A. J. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0468 · Cited by 135
Self-citationWolf, S. L., Barton, D. L., Qin, R., Wos, E. J., Sloan, J. A., Liu, H., Aaronson, N. K., Satele, D., Mattar, B. I., Green, N. B., et al. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1141-9 · Cited by 132
Shemesh, O. A., & Spira, M. E. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0586-0 · Cited by 128
Mykletun, A., Dahl, A. A., Haaland, C. F., Bremnes, R. M., Dahl, O., Klepp, O., Wist, E., & Fosså, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.048 · Cited by 126
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics
Cavaletti, G., Alberti, P., & Marmiroli, P. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70131-0 · Cited by 123
Self-citationEarly predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy
Cavaletti, G., Bogliun, G., Marzorati, L., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh348 · Cited by 118
Self-citationRole of MAPKs in platinum-induced neuronal apoptosis
Scuteri, A., Galimberti, A., Maggioni, D., Ravasi, M., Pasini, S., Nicolini, G., Bossi, M., Miloso, M., Cavaletti, G., & Tredici, G. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.01.003 · Cited by 117
Self-citationThe taxanes: toxicity and quality of life considerations in advanced ovarian cancer
Guastalla, J. P., & Dieras, V. C. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601496 · Cited by 116
Bruna, J., Udina, E., Alé, A., Vilches, J., Vynckier, A., Monbaliu, J. G., Silverman, L. R., & Navarro, X. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.02.006 · Cited by 115
Studies on the pathogenesis of vincristine‐induced neuropathy
Sahenk, Z., Brady, S. T., & Mendell, J. R. (1987) · Muscle & Nerve · doi:10.1002/mus.880100115 · Cited by 113
Dougherty, P. M., Cata, J. P., Burton, A. W., Vu, K., & Weng, H. (2007) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2006.08.006 · Cited by 110
A prospective study of suramin-induced peripheral neuropathy
Chaudhry, V., Eisenberger, M. A., Sinibaldi, V. J., Sheikh, K., Griffin, J. W., & Cornblath, D. R. (1996) · Brain · doi:10.1093/brain/119.6.2039 · Cited by 108
Persistent neuropathy after treatment with cisplatin and oxaliplatin
Brouwers, E. E. M., Huitema, A. D. R., Boogerd, W. J., Beijnen, J. H., & Schellens, J. H. M. (2009) · Acta Oncologica · doi:10.1080/02841860902806609 · Cited by 106
Persistent Mobility Disability After Neurotoxic Chemotherapy
Hile, E. S., Fitzgerald, G. K., & Studenski, S. A. (2010) · Physical Therapy · doi:10.2522/ptj.20090405 · Cited by 106
Clinical and electrophysiological studies in vincristine induced neuropathy.
Pal, P. K. (1999) · PubMed · Cited by 96
Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications
Lepper, E. R., Smith, N. F., Cox, M. C., Scripture, C. D., & Figg, W. D. (2006) · Current Drug Metabolism · doi:10.2174/138920006778017777 · Cited by 95
Carfilzomib: A Novel Second-Generation Proteasome Inhibitor
Khan, M. L., & Stewart, A. K. (2011) · Future Oncology · doi:10.2217/fon.11.42 · Cited by 95
Conlin, A. K., Seidman, A. D., Bach, A. M., Lake, D. E., Dickler, M. N., D’Andrea, G. M., Traina, T. A., Danso, M. A., Brufsky, A., Saleh, M. N., et al. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.036 · Cited by 91
The proteasome: a novel target for anticancer therapy
Montagut, C. O., Rovira, A., & Albanell, J. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0176-8 · Cited by 87
Casafont, Í., Berciano, M. T., & Lafarga, M. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9086-1 · Cited by 78
Zhang, H., Mizumachi, T., Cárcel‐Trullols, J., Li, L., Naito, A., Spencer, H. J., Spring, P. M., Smoller, B. R., Watson, A. J., Margison, G. P., et al. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm072 · Cited by 60
Neuropathic Pain in Breast Cancer Survivors: Using the ID Pain as a Screening Tool
Reyes‐Gibby, C. C., Morrow, P. K. H., Bennett, M., Jensen, M. P., & Shete, S. S. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.09.020 · Cited by 57
Matei, D. E., Miller, A. M., Monahan, P. O., Gershenson, D. M., Zhao, Q., Cella, D. F., Champion, V. L., & Williams, S. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9189 · Cited by 45
Stubblefield, M. D. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.03.008 · Cited by 44
Eribulin mesylate in the treatment of metastatic breast cancer
Cigler, T., & Jain (2012) · Biologics · doi:10.2147/btt.s19811 · Cited by 39
Antonacopoulou, A. G., Argyriou, A. A., Scopa, C. D., Kottorou, A. E., Kominea, A., Peroukides, S., & Kalofonos, H. P. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02966.x · Cited by 37
Muscle Cramps Associated with Vincristine Therapy
Haim, N., Barron, S. A., & Robinson, E. (1991) · Acta Oncologica · doi:10.3109/02841869109092444 · Cited by 28
Chon, H. J., Rha, S. Y., Im, C. K., et al. (2009) · Cancer Research and Treatment · doi:10.4143/crt.2009.41.4.196 · Cited by 28
Thalidomide and lenalidomide in multiple myeloma
Mazumder, A., & Jagannath, S. (2006) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2006.06.006 · Cited by 23
Cited by
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014) · Pain · doi:10.1016/j.pain.2014.09.020 · Cited by 1,555
“Previous reviews of CIPN have combined narrative review with expert opinion, with potential risk of bias [15,28,29].”
Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Starobova, H., & Vetter, I. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00174 · Cited by 648
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Flatters, S. J. L., Dougherty, P. M., & Colvin, L. A. (2017) · British Journal of Anaesthesia · doi:10.1093/bja/aex229 · Cited by 391
Zhang, H., Li, Y., de Carvalho-Barbosa, M., Kavelaars, A., Heijnen, C. J., Albrecht, P. J., & Dougherty, P. M. (2016) · The Journal of Pain · doi:10.1016/j.jpain.2016.02.011 · Cited by 365
Metadata
- Authors
- Grisold, W., Cavaletti, G., & Windebank, A. J.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-01
- Volume
- 14
- Issue
- suppl 4
- Pages
- iv45-iv54
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2170259378
- Cited by
- 486
- References
- 73
- FWCI
- 11.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.